- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00230776
A Controlled Pregabalin Trial In Fibromyalgia
January 22, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia
To evaluate the efficacy and safety of pregabalin compared with placebo for the relief of pain associated with fibromyalgia and improvement of function of patients with fibromyalgia
Study Overview
Study Type
Interventional
Enrollment
740
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Pfizer Investigational Site
-
-
California
-
Fresno, California, United States, 93710
- Pfizer Investigational Site
-
La Jolla, California, United States, 92037
- Pfizer Investigational Site
-
Northridge, California, United States, 91325
- Pfizer Investigational Site
-
Pismo Beach, California, United States, 93449
- Pfizer Investigational Site
-
Sacramento, California, United States, 95825
- Pfizer Investigational Site
-
San Diego, California, United States, 92103
- Pfizer Investigational Site
-
Walnut Creek, California, United States, 94598
- Pfizer Investigational Site
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Pfizer Investigational Site
-
-
Florida
-
DeLand, Florida, United States, 32720
- Pfizer Investigational Site
-
Gainesville, Florida, United States, 32610-0221
- Pfizer Investigational Site
-
Hollywood, Florida, United States, 33023
- Pfizer Investigational Site
-
Melbourne, Florida, United States, 32901
- Pfizer Investigational Site
-
Ocala, Florida, United States, 34471
- Pfizer Investigational Site
-
Ocala, Florida, United States, 34474
- Pfizer Investigational Site
-
Palm Beach Gardens, Florida, United States, 33410
- Pfizer Investigational Site
-
Palm Harbor, Florida, United States, 34684
- Pfizer Investigational Site
-
Sunrise, Florida, United States, 33351
- Pfizer Investigational Site
-
Tampa, Florida, United States, 33614
- Pfizer Investigational Site
-
Tampa, Florida, United States, 33606
- Pfizer Investigational Site
-
West Palm Beach, Florida, United States, 33407
- Pfizer Investigational Site
-
-
Illinois
-
Gurnee, Illinois, United States, 60031
- Pfizer Investigational Site
-
Moline, Illinois, United States, 61265
- Pfizer Investigational Site
-
Morton Grove, Illinois, United States, 60053
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Pfizer Investigational Site
-
Indianapolis, Indiana, United States, 46202-5250
- Pfizer Investigational Site
-
-
Iowa
-
Dubuque, Iowa, United States, 52001
- Pfizer Investigational Site
-
Dubuque, Iowa, United States, 52002
- Pfizer Investigational Site
-
-
Kansas
-
Prairie Village, Kansas, United States, 66206
- Pfizer Investigational Site
-
Pratt, Kansas, United States, 67124
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Pfizer Investigational Site
-
-
Louisiana
-
Kenner, Louisiana, United States, 70065
- Pfizer Investigational Site
-
Metairie, Louisiana, United States, 70006
- Pfizer Investigational Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Pfizer Investigational Site
-
Watertown, Massachusetts, United States, 02472
- Pfizer Investigational Site
-
Worcester, Massachusetts, United States, 01610
- Pfizer Investigational Site
-
-
Michigan
-
Lansing, Michigan, United States, 48910
- Pfizer Investigational Site
-
-
Minnesota
-
Chaska, Minnesota, United States, 55318
- Pfizer Investigational Site
-
Saint Paul, Minnesota, United States, 55101
- Pfizer Investigational Site
-
-
Missouri
-
Jefferson City, Missouri, United States, 65109
- Pfizer Investigational Site
-
Kansas City, Missouri, United States, 64106
- Pfizer Investigational Site
-
Saint Louis, Missouri, United States, 63141
- Pfizer Investigational Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68516
- Pfizer Investigational Site
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Pfizer Investigational Site
-
-
New York
-
Albany, New York, United States, 12205
- Pfizer Investigational Site
-
Endwell, New York, United States, 13760
- Pfizer Investigational Site
-
New York, New York, United States, 10022-1009
- Pfizer Investigational Site
-
West Seneca, New York, United States, 14224
- Pfizer Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Pfizer Investigational Site
-
Hickory, North Carolina, United States, 28601
- Pfizer Investigational Site
-
Hickory, North Carolina, United States, 28602
- Pfizer Investigational Site
-
Raleigh, North Carolina, United States, 27609
- Pfizer Investigational Site
-
Salisbury, North Carolina, United States, 28144
- Pfizer Investigational Site
-
Winston-Salem, North Carolina, United States, 27103
- Pfizer Investigational Site
-
-
North Dakota
-
Minot, North Dakota, United States, 58701
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Pfizer Investigational Site
-
Cincinnati, Ohio, United States, 45227
- Pfizer Investigational Site
-
Cincinnati, Ohio, United States, 45245
- Pfizer Investigational Site
-
Dayton, Ohio, United States, 45402
- Pfizer Investigational Site
-
Toledo, Ohio, United States, 43623
- Pfizer Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104-5428
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Pfizer Investigational Site
-
Bethlehem, Pennsylvania, United States, 18015
- Pfizer Investigational Site
-
Norristown, Pennsylvania, United States, 19401
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15213
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15218
- Pfizer Investigational Site
-
-
South Carolina
-
Goose Creek, South Carolina, United States, 29445
- Pfizer Investigational Site
-
Mount Pleasant, South Carolina, United States, 29464
- Pfizer Investigational Site
-
Myrtle Beach, South Carolina, United States, 29572
- Pfizer Investigational Site
-
Summerville, South Carolina, United States, 29485
- Pfizer Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Pfizer Investigational Site
-
Knoxville, Tennessee, United States, 37909-1900
- Pfizer Investigational Site
-
Milan, Tennessee, United States, 38358
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37203
- Pfizer Investigational Site
-
-
Texas
-
Bedford, Texas, United States, 76021
- Pfizer Investigational Site
-
Georgetown, Texas, United States, 78626
- Pfizer Investigational Site
-
Houston, Texas, United States, 77030
- Pfizer Investigational Site
-
Killeen, Texas, United States, 76549
- Pfizer Investigational Site
-
Lake Jackson, Texas, United States, 77566
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78229
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78213
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84102-1571
- Pfizer Investigational Site
-
-
Vermont
-
Woodstock, Vermont, United States, 05091
- Pfizer Investigational Site
-
-
Virginia
-
Virginia Beach, Virginia, United States, 23455
- Pfizer Investigational Site
-
-
Washington
-
Everett, Washington, United States, 98201
- Pfizer Investigational Site
-
Spokane, Washington, United States, 99204
- Pfizer Investigational Site
-
Spokane, Washington, United States, 99216
- Pfizer Investigational Site
-
Tacoma, Washington, United States, 98405
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53209
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites.
- Patients must have a score of >40 mm on the Visual Analog Scale
Exclusion Criteria:
- Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
To evaluate the efficacy of pregabalin for pain relief by comparing the mean pain score between treatment groups and placebo.
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
To evaluate the efficacy of pregabalin for improvement in sleep, fatigue, health-related quality of life, functioning and mood disturbance associated with fibromyalgia. To evaluate safety and tolerability.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27.
- Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125.
- Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin Pharmacother. 2010 Dec;11(17):2805-12. doi: 10.1517/14656566.2010.525217. Epub 2010 Nov 2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2005
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
September 29, 2005
First Submitted That Met QC Criteria
September 29, 2005
First Posted (Estimate)
October 3, 2005
Study Record Updates
Last Update Posted (Actual)
January 26, 2021
Last Update Submitted That Met QC Criteria
January 22, 2021
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Fibromyalgia
- Myofascial Pain Syndromes
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
- A0081077
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.